BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24185441)

  • 1. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
    Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
    J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
    Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
    Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
    Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
    Vellimana AK; Recinos VR; Hwang L; Fowers KD; Li KW; Zhang Y; Okonma S; Eberhart CG; Brem H; Tyler BM
    J Neurooncol; 2013 Feb; 111(3):229-36. PubMed ID: 23224713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
    Zhao S; Zhang Y; Wang L; Yang L; Zou L; Gao F
    Cancer Biol Ther; 2019; 20(1):65-72. PubMed ID: 30136881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
    Brem S; Tyler B; Li K; Pradilla G; Legnani F; Caplan J; Brem H
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):643-50. PubMed ID: 17256133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
    Magaña-Maldonado R; Manoutcharian K; Hernández-Pedro NY; Rangel-López E; Pérez-De la Cruz V; Rodríguez-Balderas C; Sotelo J; Pineda B
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):291-301. PubMed ID: 24337403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
    Li R; Tang D; Zhang J; Wu J; Wang L; Dong J
    J Neurooncol; 2014 Jan; 116(1):25-30. PubMed ID: 24065569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
    Ulasov I; Thaci B; Sarvaiya P; Yi R; Guo D; Auffinger B; Pytel P; Zhang L; Kim CK; Borovjagin A; Dey M; Han Y; Baryshnikov AY; Lesniak MS
    Cancer Med; 2013 Aug; 2(4):457-67. PubMed ID: 24156018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
    Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
    Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current evidence of temozolomide and bevacizumab in treatment of gliomas.
    Nanegrungsunk D; Onchan W; Chattipakorn N; Chattipakorn SC
    Neurol Res; 2015 Feb; 37(2):167-83. PubMed ID: 25033940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
    Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
    J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.